The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M) an increase of 18% on
the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s
prostate cancer imaging product Illuccix®.
U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth
between Q3 2023 and Q4 2023.
Ann: Telix Q1 2024 Revenue and Business Update, page-2
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.05 |
Change
-0.460(2.97%) |
Mkt cap ! $4.973B | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.57 | $14.97 | $20.59M | 1.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1999 | $15.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.06 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$15.06 |
Change
-0.460 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| $15.43 | $15.56 | $14.99 | 650525 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| TLX (ASX) Chart |